Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05714371 · ClinicalTrials.gov registry record
Retrospective Assessment of Adverse Events-related Healthcare Resource Utilization and Costs of Immune Checkpoint Inhibitor and Targeted Therapy for Adjuvant Treatment of Melanoma
A clinical trial, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- 618
- Enrollment target
NCT05714371 is a clinical trial that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 618 participants.
The verdict
NCT05714371 has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- 618 participants
- Enrollment target
Study Summary
This was a retrospective cohort study using the PharMetrics database. The analysis was conducted using the most recent 5 years of data from the database, January 1, 2015, to October 30, 2020. Included patients were followed for outcome evaluation from the index date (first prescription of treatment, immunotherapy \[IO\], or targeted therapy \[TT\] following diagnosis of non-metastatic malignant melanoma and evidence of first lymph node resection), until the first occurrence or end of continuous eligibility or end of the study period.
Interventions
- DRUG Pembrolizumab
- DRUG Nivolumab
- DRUG Ipilimumab + nivolumab
- DRUG Dabrafenib + trametinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 618 participants |
| Start Date | 2021-10-02 |
| Est. Completion | 2022-01-27 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05714371
The ClinicalTrials.gov registry entry for NCT05714371 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 618 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Pembrolizumab is the first listed.
NCT05714371 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05714371 about?
NCT05714371 is a clinical study titled "Retrospective Assessment of Adverse Events-related Healthcare Resource Utilization and Costs of Immune Checkpoint Inhibitor and Targeted Therapy for Adjuvant Treatment of Melanoma". This was a retrospective cohort study using the PharMetrics database. The analysis was conducted using the most recent 5 years of data from the database, January 1, 2015, to October 30, 2020. Included patients were followed for outcome evaluation from the index date (first prescription of treatment,...
What is the current status of trial NCT05714371?
This trial is currently completed. The enrollment target is 618 participants. The study started on 2021-10-02. Estimated completion is 2022-01-27.
What interventions are being tested in trial NCT05714371?
The interventions under investigation include: Pembrolizumab (DRUG), Nivolumab (DRUG), Ipilimumab + nivolumab (DRUG), Dabrafenib + trametinib (DRUG).
Who is sponsoring clinical trial NCT05714371?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.